- Home
- MAZE vs ORIC Comparison
MAZE vs ORIC Comparison
Compare MAZE & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- ORIC
- Stock Information
- Founded
- MAZE 2018
- ORIC 2014
- Country
- MAZE United States
- ORIC United States
- Employees
- MAZE N/A
- ORIC N/A
- Industry
- MAZE
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- MAZE
- ORIC Health Care
- Exchange
- MAZE NYSE
- ORIC Nasdaq
- Market Cap
- MAZE 367.0M
- ORIC 362.9M
- IPO Year
- MAZE 2025
- ORIC 2020
- Fundamental
- Price
- MAZE $16.93
- ORIC $11.03
- Analyst Decision
- MAZE Strong Buy
- ORIC Strong Buy
- Analyst Count
- MAZE 4
- ORIC 9
- Target Price
- MAZE $23.50
- ORIC $18.29
- AVG Volume (30 Days)
- MAZE 129.8K
- ORIC 878.8K
- Earning Date
- MAZE 08-14-2025
- ORIC 08-11-2025
- Dividend Yield
- MAZE N/A
- ORIC N/A
- EPS Growth
- MAZE N/A
- ORIC N/A
- EPS
- MAZE 0.34
- ORIC N/A
- Revenue
- MAZE $167,500,000.00
- ORIC N/A
- Revenue This Year
- MAZE N/A
- ORIC N/A
- Revenue Next Year
- MAZE N/A
- ORIC N/A
- P/E Ratio
- MAZE $53.00
- ORIC N/A
- Revenue Growth
- MAZE N/A
- ORIC N/A
- 52 Week Low
- MAZE $6.71
- ORIC $3.90
- 52 Week High
- MAZE $18.50
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- ORIC 64.08
- Support Level
- MAZE N/A
- ORIC $10.60
- Resistance Level
- MAZE N/A
- ORIC $11.57
- Average True Range (ATR)
- MAZE 0.00
- ORIC 0.57
- MACD
- MAZE 0.00
- ORIC -0.08
- Stochastic Oscillator
- MAZE 0.00
- ORIC 72.32
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.